#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Small cell lung cancer limited stage Pulmonary tuberculosis Thrombotic microangiopathy Metabolic disorder Fontan procedure Microvillous inclusion disease Amyloidosis Andersen-Tawil syndrome Juvenile idiopathic arthritis Oesophageal atresia Hypomagnesaemia Urethral valves Cutaneous T-cell lymphoma stage II Autoimmune hepatitis Dilated cardiomyopathy More trials…

    Learn about Rare Diseases

    Osteosarcoma recurrent – Life with Disease Pelizaeus-Merzbacher disease – Treatment Angelman’s syndrome – Diagnostics Marginal zone lymphoma Haemophilia A without inhibitors Krabbe’s disease – Trials in Disease Mucopolysaccharidosis – Trials in Disease Atypical teratoid/rhabdoid tumour of CNS – Trials in Disease Rosai-Dorfman syndrome Toxic epidermal necrolysis – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Glibenclamide Prasugrel Brimonidine Iodixanol Vonicog Alfa Sot102 A24110He Ibuprofen Litifilimab REGN7999 Azd5004 Hyoscine Butylbromide Lucerastat Mps-106 Tiotropium Interferon Beta-1B Nirmatrelvir Sar-443579 Syn2 Certolizumab Pegol More therapies…

    Learn about Your Condition

    Lymphoma HIV infection Fontan procedure Chondrosarcoma Paresis Metastatic malignant melanoma Pemphigoid Bipolar disorder Eye disorder Amyloidosis Brain injury Eosinophilic oesophagitis Lower limb fracture Post-traumatic headache Osteopenia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Spinal muscular atrophy

  • Study on the Safety and Efficacy of RO7204239 and Risdiplam for Patients with Spinal Muscular Atrophy

    Not recruiting

    4 1 1
    Investigated Diseases:
    • Spinal muscular atrophy
    Belgium Croatia France Germany Italy The Netherlands +3

  • Study of Clenbuterol vs Placebo in Adult Patients with Spinal and Bulbar Muscular Atrophy (SBMA)

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Bulbospinal muscular atrophy congenital
    • Spinal muscular atrophy
    Investigated Drugs:
    • Clenbuterol Hydrochloride
    Italy

  • Study of NMD670 tablets to improve muscle strength in adults with Type 3 spinal muscular atrophy who can walk

    Not recruiting

    2 1
    Investigated Diseases:
    • Spinal muscular atrophy
    Investigated Drugs:
    • Nmd670
    Belgium Denmark Germany Italy The Netherlands Spain

  • Study on the Safety and Pharmacokinetics of Risdiplam in Infants with Spinal Muscular Atrophy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Spinal muscular atrophy
    Investigated Drugs:
    • Risdiplam
    Belgium Germany Italy The Netherlands Norway Poland

  • Study on Long-Term Safety and Effects of Apitegromab in Patients with Type 2 and Type 3 Spinal Muscular Atrophy Who Completed Previous Trials

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Spinal muscular atrophy
    Investigated Drugs:
    • Apitegromab
    Belgium France Germany Italy The Netherlands Poland +1

  • Long-term Safety and Efficacy Study of Onasemnogene Abeparvovec in Patients with Spinal Muscular Atrophy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Spinal muscular atrophy
    Investigated Drugs:
    • Onasemnogene Abeparvovec
    Belgium France Italy
Previous Page
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!